Ultragenyx Pharmaceutical focuses on developing treatments for rare genetic diseases globally. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company also has several product candidates in development, such as DTX401, DTX301, UX143, GTX-102, UX111, UX701, and UX053. Ultragenyx collaborates with multiple organizations, including Kyowa Kirin Co., Ltd. and Regeneron. The company was incorporated in 2010 and is headquartered in Novato, California. It focuses on identifying, acquiring, developing, and commercializing novel products for rare diseases.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 0.3 |